Fate's closely watched stem cell-derived NK program raises red flag over durability of response
At the cutting edge of oncology research, biotechs like Fate Therapeutics are looking for ways to craft next-gen cell therapies without relying on patients’ own cells. An early peek at the company’s clinical data looks promising, but will iffy durability results prove a roadblock?
Fate on Thursday revealed an early cut of Phase I data for its FT596 and FT516 induced pluripotent stem cell-derived natural killer cell programs that revealed potential red flags on one of the therapies’ durability over time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.